GeoVax Labs
GOVXGeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines against infectious diseases and cancers.
Table of contents
Earnings
Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines against infectious diseases and cancers. The company utilizes its proprietary Modified Vaccinia Ankara (MVA) platform to design and manufacture candidates that stimulate both humoral and cellular immune responses. Its core value proposition lies in creating durable, multi-antigenic treatments for global health threats and oncology indications.
GeoVax is a specialized clinical-stage player utilizing a differentiated MVA viral vector platform to compete in the high-stakes vaccine and oncology markets.
Questions, answered.
- What is GeoVax Labs's market cap?
- GeoVax Labs (GOVX) has a market capitalization of $4.0M and trades on NASDAQ.
- Who are GeoVax Labs's competitors?
- GeoVax Labs's key competitors include Moderna, Inc., Pfizer Inc., PDS Biotechnology Corporation Common Stock, and others. These companies compete in similar markets and product categories.
- Who does GeoVax Labs partner with?
- GeoVax Labs's notable partners include National Institutes of Health, City of Hope.
- Where is GeoVax Labs headquartered?
- GeoVax Labs is headquartered in United States of America and employs approximately 17 people. It has been publicly traded since 1995.